Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens
Author:
Affiliation:
1. From the Departments of Medical Oncology and Biostatistics, Dana-Farber Cancer Institute; the University of Leeds, West Yorkshire, United Kingdom; and the Department of Medicine, Brigham and Woman's Hospital, Harvard Medical School, Boston, MA.
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/103/2/656/1694483/zh800204000656.pdf
Reference54 articles.
1. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88: 2787-2793.
2. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995;13: 1312-1322.
3. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol. 2000;18: 2273-2281.
4. Reece DE, Shepherd JD, Klingemann HG, et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15: 117-123.
5. Majolino I, Corradini P, Scime R, et al. High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. Bone Marrow Transplant. 2003;31: 767-773.
Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events;Expert Review of Hematology;2022-06-03
2. Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study;Bone Marrow Transplantation;2021-11-29
3. Clinical experience of CAR T cells for multiple myeloma;Best Practice & Research Clinical Haematology;2021-09
4. Chimeric Antigen Receptor T Cells for Multiple Myeloma;The Cancer Journal;2021-03
5. Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma;Biology of Blood and Marrow Transplantation;2020-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3